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This study aimed to investigate the expression pattern and prognostic value of friend leukemia virus integration 1
(FLI-1) in nasopharyngeal carcinoma (NPC). Immunohistochemistry (IHC) staining of FLI-1 was performed in
specimens from 198 untreated NPC patients. Ninety-nine patients were randomly assigned to the training set to
analyze the prognostic value of FLI-1 and other clinicopathological characteristics, while the others were assigned
to the testing set for validation. Clinicopathological data were compared using the Pearson chi-square test.
Univariate and multivariate analyses were performed using the Cox proportional hazards model to test
independent prognostic factors and calculate the hazard ratio (HR) and 95% confidence interval (CI). Cytoplasmic
FLI-1 expression positively correlated with N stage, distant metastasis and death (Pb0.05) and also predicted
poorer overall survival (OS) (P=0.014), distant metastasis-free survival (DMFS) (P=0.010), progression-free survival
(PFS) (P=0.031). In multivariate analysis, FLI-1 expression and clinical stage were both independent prognostic
factors of poor OS and DMFS. Prognoses of patients in the training set, the testing set, and the entire set were
clearly divided into four risk subgroups by supplementing FLI-1 with clinical stage. These results indicate that FLI-1
expression is an independent prognostic factor for NPC patients and suggest that supplementing FLI-1 with
clinical stage could be helpful for more accurate risk definition.
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Nasopharyngeal carcinoma (NPC), the most common cancer
originating from nasopharynx, is a unique type of head and neck
malignancy in terms of its unbalanced distribution, poor differentia-
tion, strong propensity to metastasize to regional lymphatic and/or
distant organs, and chemo-radiosensitivity. NPC is most prevalent in
the Guangdong Province of the southern China and universally
associated with Epstein-Barr virus infection, with most classified as the









494 Prognostic Significance of FLI-1 Liang et al. Translational Oncology Vol. 7, No. 4, 2014ment of diagnosis techniques, irradiation and chemo-radiotherapy,
while locoregional control rate has increased greatly in the past few
decades, however, the incidence of distant metastasis has not decreased
significantly, as high as 16% to 30% [2,3], which becomes the leading
cause of treatment failure nowadays. Currently, prediction of NPC
survivals is mainly based on the TNM staging system. However,
different outcomes are observed in NPC patients with the same clinical
stage of tumors after receiving similar standard treatment, indicating a
pressing need of prognostication utilizing some biomarkers and the
TNM staging to guide individualized treatment.
Friend leukemia virus integration 1 (FLI-1), which was first
identified in erythroleukemia induced by Friend Murine Leukemia
Virus (F-MuLV) [4], is a new member of the E26 transformation-
specific (ETS) transcription factor family. FLI-1, which is localized
within the 240 kb of the ETS-1 locus on mouse chromosome 9 and
on human chromosome 11q23 [4,5], is activated through retroviral
insertion mutagenesis in most F-MuLV-induced erythroleukemias.
Activated FLI-1 can alter EPO/EPO-receptor signaling pathway and
the Ras pathway, blocking erythroid differentiation and apoptosis and
leading to massive EPO-independent proliferation of erythroblasts
[6]. In addition, FLI-1 is also involved in various malignancy
formation and progression in vitro and/or in vivo, including Ewing’s
sarcoma [7], melanoma [8], breast cancer [9], lymphoma [10,11] and
head and neck squamous cell cancer (HNSCC) [12], and tumor
micro-angiogenesis [13].
Studies on the role of FLI-1 expression in NPC are rare. FLI-1 was
found to be over-expressed in the metastatic NPC cell line, the 5-8F
cell line, in the research by Yang et al [14]. However, little is known
about the FLI-1 expression and prognostication of NPC patients.
Therefore, this study aims to detect FLI-1 expression in NPC tissue
samples by immunohistochemistry (IHC), analyze the associations
between FLI-1 expression and clinicopathological characteristics, and
evaluate the prognostic value of FLI-1 for NPC patients.Figure 1. Immunohistochemical (IHC) staining for FLI-1 expression in
mainly observed in the cytoplasm of NPC cells. (A) Positive contr
expression (SP×400); (C) low expression (SP×400); (D) modera
adenoid-like differentiated tumors highly expressed FLI-1 (black
arrows) (SP×400).Materials and Methods
Patients Selection and Samples Collection
This study was approved by the Clinical Ethics Review Board of
Sun Yat-sen University Cancer Center. All the patients signed
informed consent documents before participating in the study.
Patients were recruited according to the following criteria: histolog-
ically diagnosed NPC with available biopsy sample; newly proven and
non-metastatic NPC; no other malignancy or prior anti-cancer
treatment; continuously finished at least radiotherapy at the Cancer
Centre of Sun Yat-sen University with complete and detailed medical
records and regular follow-ups. A total of consecutive 198 patients
were eligible, who were diagnosed between May 2005 and December
2006. Medical files were reviewed retrospectively and patients were
restaged based on the American Joint Committee on Cancer (AJCC)
staging system 2010 clinical classification (the seventh edition). All
198 patients were histologically diagnosed with differentiated non-
keratinized carcinoma or undifferentiated non-keratinized carcinoma.
The tumor specimens were obtained by biting biopsy from primary
NPC, prior to treatment, and processed through formalin fixation for
at least 8 hours and paraffin embedment.Pretreatment Evaluation
Patients underwent a routine pretreatment evaluation including
history, physical examination of the head and neck, optic fiber
nasopharyngoscopy, nasopharynx and neck magnetic resonance imaging
(MRI), chest X-ray, the abdominal ultrasonography, bone scanning, a
complete blood count and biochemical profile. The serological titer of
Epstein-Barr virus immunoglobulin A antibodies against viral capsid
antigen (EBV VCA-IgA) was measured using an immunoenzymic assay.
The serum titer of Epstein-Barr virus immunoglobulin A antibodies
against early antigen (EBV EA-IgA) was further measured using an
immunoenzymic assay by Raji cell line. The serologic antienzyme rate ofnasopharyngeal carcinoma (NPC). Positive FLI-1 expression was
ol for FLI-1 IHC staining in rectal cancer (SP×400); (B) Negative
te expression (SP×400); (E) high expression (SP×400); (F) the
arrows), with negative expression in the carcinoma nests (red















Male 148 26 (17.6) 44 (29.7) 0.212 27(18.2) 51(34.5) 0.602
Female 50 7 (14.0) 22 (44.0) 6(12.0) 15(30.0)
Age (years)
≤50 130 26 (20.0) 44 (33.8) 0.212 20(15.4) 40(30.8) 1.000
N50 68 7 (10.3) 22(32.4) 13(19.1) 26(38.2)
T classification a
T1-2 98 14 (14.3) 33 (33.7) 0.477 13(13.3) 38(38.8) 0.088
T3-4 100 19 (19.0) 33 (33.0) 20(20.0) 28(28.0)
N classification a
N0-1 125 13 (10.4) 49 (39.2) 0.001 15(12.0) 48(38.4) 0.008
N2-3 73 20 (27.4) 17 (23.3) 18(24.7) 18(24.7)
Clinical stage a
I~II 64 8 (12.5) 22 (34.4) 0.353 9(14.1) 25(39.1) 0.295
III~IVb 134 25 (18.7) 44 (32.8) 24(17.9) 41(30.6)
Histological type
U 189 32 (16.9) 63(33.3) 1.000c 30(15.9) 64(33.9) 0.417c
D 9 1 (11.1) 3 (33.3) 3(33.3) 2(22.2)
EBV VCA-IgA titre
b1:480 131 22 (16.8) 42 (32.1) 0.915 19(14.5) 48(36.6) 0.059
≥1:480 60 11 (18.3) 20 (33.3) 14(23.3) 15(25.0)
EBV EA-IgA titre
b1:30 96 18 (18.8) 30 (31.3) 0.568 12(12.5) 36(37.5) 0.053
≥1:30 95 15 (15.8) 32 (33.7) 21(22.1) 27(28.4)
AER
≤49% 94 15 (16.0) 25 (26.6) 0.205 17(18.1) 37(39.4) 0.639
N49% 81 12 (14.8) 36 (44.4) 12(14.8) 21(25.9)
Diameters of lymph node b
b 2.0cm 91 16 (17.6) 29 (31.9) 0.669 11(12.1) 35(38.5) 0.064
≥ 2.0cm 107 17 (15.9) 37 (34.6) 22(20.6) 31(29.0)
Lymph node extracapsular spread
Yes 46 9(19.6) 14(30.4) 0.501 9(19.6) 14(30.4) 0.501
No 152 24(15.8) 52(34.2) 24(15.8) 52(34.2)
Chemotherapy
Yes 138 22(15.9) 49(35.5) 0.430 27(19.6) 40(29.0) 0.033
No 60 11(18.3) 17(28.3) 6(10.0) 26(43.3)
Locoregional failure
Yes 32 9 (28.1) 8 (25.0) 0.060 6(18.8) 9(28.1) 0.552
No 166 24 (14.5) 58 (34.9) 27(16.3) 57(34.3)
Distant metastasis
Yes 55 16 (29.1) 14 (25.5) 0.005 15(27.3) 10(18.2) 0.001
No 143 17 (11.9) 52 (36.4) 18(12.6) 56(39.2)
Death
Yes 60 18 (30.0) 17 (28.3) 0.005 13(21.7) 12(20.0) 0.022
No 138 15 (10.5) 49 (34.3) 20(14.0) 54(37.8)
a the American Joint Committee on Cancer (AJCC) staging system 2010 clinical classification; b minimal axial diameter of lymph node based on magnetic resonance imaging; c continuity correction; AER
denotes serologic antienzyme rate of Epstein-Barr virus DNase-specific neutralizing antibody; EBV VCA-IgA titer denotes the serological titer of Epstein-Barr virus immunoglobulin A antibodies against
viral capsid antigen; EBV EA-IgA titer denotes the serum titer of Epstein-Barr virus immunoglobulin A antibodies against early antigen; U, undifferentiated non-keratinized carcinoma; D, differentiated
non-keratinized carcinoma.
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tested by an automatic liquid scintillation counter, using the mixture of
patient sera and the lysate of an EBV-infected Raji cell line which was
previously treated with croton oil and n-butanoic acid to induce DNase
antigen production.
Treatment
All patients received continuous definitive radiotherapy: 177/198
(89.4%) patients were treated with two-dimensional radiotherapy
(2D-RT) and 21/198 (10.6%) patients received intensity-modulated
radiotherapy (IMRT). Total dose delivered to the primary tumor
site was 64-80 Gy, with a mean of 70.85 Gy (standard deviation,
SD: ±4.27 Gy) and a median of 70 Gy respectively. Dose for
positive lymph node was 56-70 Gy, with a mean of 63.87 Gy
(SD: ±3.93 Gy) and a median of 64 Gy respectively. The
prophylactic dose was 50-56 Gy.One hundred and thirty-eight patients received platinum-based
chemotherapy: 72 patients received neoadjuvant chemotherapy, 100
patients received concurrent chemotherapy and 11 patients received
adjuvant chemotherapy. The institutional guidelines for NPC during
this research period recommended no chemotherapy for T1-2N0M0
(the AJCC staging system 2002 clinical classification, the sixth
edition) patients, whose diseases were classified as stage I and stage II
with no enlarged lymph nodes. However, concurrent chemoradio-
therapy was required for stage II disease with positive lymph nodes
and concurrent chemoradiotherapy with or without neoadjuvant/
adjuvant chemotherapy was necessary for stage III to IVa-b patients.
Neoadjuvant chemotherapy consisted of two cycles of cisplatin
(80 mg/m2) by intravenous drip and 5-fluorouracil (5-Fu) (4 g/m2)
by continuous intravenous infusion for 120 hours every three weeks.
Concurrent chemotherapy consisted of two to three cycles of cisplatin
(80 mg/m2) by intravenous drip on weeks 1, 4 and/or 7 during
Figure 2. Survival curves of nasopharyngeal carcinoma patients in the training set stratified by FLI-1 expression. FLI-1 was associated
with prognoses. (A) Overall survival curves of patients with negative and positive FLI-1 expression; (B) Distant metastasis-free
survival curves of patients with negative and positive FLI-1 expression; (C) Progression-free survival curves of patients with
negative and positive FLI-1 expression; (D) Locoregional failure-free survival curves of patients with negative and positive FLI-1
expression.
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by intravenous drip and 5-Fu (4 g/m2) continuous intravenous infusion
for 120 hours every four weeks.Follow-up
Patients were advised to attend follow-up visit every three months
for the first three years, every six months for the fourth and fifth years,
and every year thereafter. The primary end point was overall survival
(OS), and the secondary end points were distant metastasis-free
survival (DMFS), progression-free survival (PFS) and locoregional
failure-free survival (LRFS). The up-mentioned end points were
defined as followed: OS, the time from finishing radiotherapy to the
date of death or the latest visit date if patients were still alive; DMFS,
the time from finishing radiotherapy to the date of distant metastasis
or the latest visit date when censored; LRFS, the time from finishing
radiotherapy to the date of failure in nasopharynx and/or cervical
lymph nodes or the latest visit date when censored; PFS, the time
from finishing radiotherapy to the date of relapse at any site or the
latest visit date when censored.Immunohistochemistry (IHC)
The paraffin-embedded tumor tissues were cut into 4μm slices,
dried at 60 °C for at least six hours, deparaffinized in xylene for four
times, rehydrated in graded alcohols, microwaved in EDTA buffer
solution to retrieve tissue antigen, and incubated in 3% H2O2
solution for ten minutes to eliminate endogenous peroxidase activity.
The slices were incubated in anti-FLI-1 rabbit polyclonal antibody
(1:100 dilution, SC-356, SANTA CRUZ BIOTECHNOLOGY,
Inc.) at 37 °C for 60 minutes and next in anti-rabbit secondary
immunoglobulin G antibody solution labeled by horse radish
peroxidase (DAKO, Denmark) at 37 °C for 30 minutes in the same
humidified chamber. Staining was visualized using diaminobenzi-
dine (DAKO, Denmark) staining, followed by hematoxylin nuclear
counterstaining. Finally, the slices were dehydrated by graded
alcohols and mounted by neutral transparent gum. Negative controls
were performed by omitting the primary antibody. Positive controls
were done in rectal cancer sections (Figure 1A).
Histological and IHC staining were evaluated by two independent
pathologists who were blind to clinicopathological and survival data of
the patients. Any different evaluation was discussed until a consensus
Table 2. Univariate analysis with the Cox proportional hazards model for OS, DMFS, PFS and
LRFS of nasopharyngeal carcinoma patients in the training set (n=99)
Prognostic factors P HR 95% CI for HR
Lower Upper
OS
Age (years) (N50 vs.≤50) 0.636 1.188 0.582 2.427
Gender (female vs. male) 0.299 0.658 0.299 1.449
Pathology (U vs. D) 0.112 1.878 0.864 4.082
T stage (T3-4 vs. T1-2) 0.078 1.874 0.932 3.766
N stage (N2-3 vs. N0-1) b0.001 5.571 2.669 11.626
Clinical stage (III~IVb vs. I~II) 0.004 5.731 1.754 18.724
Fli-1 (positive vs. negative) 0.017 2.240 1.154 4.348
AER (N49% vs. ≤49%) 0.105 1.876 0.876 4.013
Chemotherapy (yes vs. no) 0.178 1.768 0.772 4.048
DMFS
Age (years) (N50 vs.≤50) 0.806 0.904 0.402 2.030
Gender (female vs. male) 0.032 0.316 0.110 0.905
Pathology (U vs. D) 0.182 1.813 0.757 4.343
T stage (T3-4 vs. T1-2) 0.284 1.491 0.718 3.095
N stage (N2-3 vs. N0-1) b0.001 4.343 2.025 9.314
Clinical stage (III~IVb vs. I~II) 0.043 2.687 1.031 7.001
Fli-1 (positive vs. negative) 0.013 2.481 1.210 5.087
AER (N49% vs. ≤49%) 0.660 1.200 0.533 2.703
Chemotherapy (yes vs. no) 0.095 2.259 0.867 5.885
PFS
Age (years) (N50 vs.≤50) 0.805 0.903 0.402 2.028
Gender (female vs. male) 0.015 0.228 0.069 0.752
Pathology (U vs. D) 0.185 1.811 0.753 4.352
T stage (T3-4 vs. T1-2) 0.036 2.310 1.058 5.044
N stage (N2-3 vs. N0-1) b0.001 4.968 2.267 10.883
Clinical stage (III~IVb vs. I~II) 0.012 4.638 1.406 15.295
Fli-1 (positive vs. negative) 0.035 2.157 1.054 4.416
AER (N49% vs. ≤49%) 0.409 1.417 0.620 3.239
Chemotherapy (yes vs. no) 0.115 2.166 0.829 5.660
LRFS
Age (years) (N50 vs.≤50) 0.896 1.072 0.377 3.043
Gender (female vs. male) 0.054 0.137 0.018 1.034
Pathology (U vs. D) 0.835 1.187 0.237 5.943
T stage (T3-4 vs. T1-2) 0.052 3.039 0.991 9.321
N stage (N2-3 vs. N0-1) 0.132 2.080 0.802 5.394
Clinical stage (III~IVb vs. I~II) 0.044 3.476 1.037 11.658
Fli-1 (positive vs. negative) 0.084 2.313 0.892 5.996
AER (N49% vs. ≤49%) 0.986 0.991 0.359 2.734
Chemotherapy (yes vs. no) 0.068 3.085 0.920 10.347
Abbreviations: OS, overall survival; DMFS, distant metastasis-free survival; PFS, progression-free
survival; LRFS, locoregional failure-free survival; HR, hazard ratio; CI, confidence interval;
U, undifferentiated non-keratinized carcinoma; D, differentiated non-keratinized carcinoma; vs., versus.
AER denotes serologic antienzyme rate of Epstein-Barr virus DNase-specific neutralizing antibody.
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(original magnification was 400 multiples). FLI-1 IHC staining was
evaluated using a semiquantitative scoring system incorporating the
percentage of positively stained cancer cells and the staining intensity.
The criteria were detailed as followed: 0% (0), 1%~25% (1), 26%
~50% (2), 51%~75% (3), 76%~100% (4); no staining (0), light yellow
weak staining (1), yellow brown moderate staining (2), brown strong
staining (4). The synthesizing evaluation score ranged from 0 to 7.
Tumors with scores ≥ 4 were defined as high FLI-1 expression, tumors
with scores = 3 were considered as moderate FLI-1 expression, tumors
with scores ≤ 2 were designated as low FLI-1 expression and tumors
with scores =0 were regarded as negative FLI-1 expression.
Statistical Analysis
Statistical analysis was performed using Statistical Package for the
Social Sciences, version 13.0 (SPSS, Chicago, IL, USA) and two-tailed
P values b 0.05 were considered statistically significant. A random
number table was generated for assigning patients to either the trainingset or the testing set. The Pearson chi-square test of independence was
used to analyze the associations between clinicopathological character-
istics and FLI-1 IHC expression. Differences of actuarial survival rates
were determined by the Kaplan-Meier method and the log-rank test.
The life-tables method was employed to calculate cumulative survival
rates. Univariate and multivariate analysis were both performed using
the Cox proportional hazardsmodel (entermethod) to test independent
prognostic factors and calculate the hazard ratio (HR) and 95%
confidence interval (CI) as well. Ninety-nine patients were randomly
assigned to the training set, which was used to analyze prognostic factors
and establish a prognostic model. The remaining patients were assigned
to the testing set for validation.
Results
Patient Clinical Characteristics and Follow-up Outcomes
The follow-up visit data were updated in July 2012, and the range
was between 2.3 and 86.6 months with a median of 62.8 months. For
all the patients, the median age was 46 years (range: 16~75 years). A
summary of clinical characteristics was presented in Table 1.
Sixty patients died during follow-up, with a median time to death of
38.2months (range: 2.3~73.5months). The 3, 5 and 7 yearOS for all the
patients were 78%, 67% and 65%, respectively. Fifty-five patients
developed distant metastasis, with a median time of 22.3 months (range:
5.1~56.4 months). The 3, 5 and 7 year DMFS for the whole patients
were 73%, 71% and 71%, respectively. Thirty-two patients experienced
nasopharyngeal and/or cervical lymph nodes failure, with a median time
to failure of 23.6 months (range: 2.3~64.9 months). The 3, 5 and 7 year
LRFS for all the patients were 85%, 82% and 80%, respectively.
Immunohistochemical Expression of FLI-1 in NPC
Positive FLI-1 expression was mainly localized in the cytoplasm of
NPC cells in sixty-six patients (33.3%): seventeen patients (8.6%)
with high expression, twenty patients (10.1%) with moderate
expression and twenty-nine (14.6%) patients with low expression.
Negative FLI-1 expression was observed in 66.7% (132/198) of the
tumors. Representative images of FLI-1 IHC staining in NPC tissues
are shown in Figure 1B-E. The adenoid-like differentiated tumors,
which constituted small portion of differentiated or undifferentiated
non-keratinized carcinoma, highly expressed FLI-1 (5/198, 2.5%), as
shown in Figure 1F.Correlation between FLI-1 Expression and Clinicopathological
Characteristics
The impact of FLI-1 expression levels on OS was analyzed using the
Kaplan-Meier method and the log-rank test to identify that positive
FLI-1 expression was predictive of poor OS (Figure 2A). So the status of
positive or negative expression was chosen for the subsequent binary
variable analysis. In the training set, gender, age, T classification, clinical
stage, histological type, EBV EA-IgA titre, EBV VCA-IgA titre, AER,
axial diameter of lymph node (b2.0cm versus ≥ 2.0cm), lymph node
extracapsular spread, chemotherapy, or locoregional failure was not
associated with FLI-1 expression. However, positive FLI-1 expression
correlatedwith advancedNclassification (P=0.001),metastasis (P=0.005)
and death (P=0.005). A similar association was verified in the testing set
except for chemotherapy (Table 1).
FLI-1 Expression in Predicting the Survival of NPC
In the training set, the 6-year OS rates for the positive FLI-1
expression group and the negative FLI-1 expression groupwere 37% and
Table 3. Multivariate analysis with the Cox proportional hazards model for OS and DMFS of nasopharyngeal carcinoma patients in the training set (n=99)
Prognostic factors P HR 95% CI for HR Prognostic factors P HR 95% CI for HR
Lower Upper Lower Upper
I OS I DMFS
Age (years) (N50 vs. ≤50) 0.468 1.351 0.599 3.051 Age (years) (N50 vs. ≤50) 0.883 1.070 0.432 2.651
Gender (female vs. male) 0.499 0.747 0.321 1.739 Gender (female vs. male) 0.054 0.297 0.086 1.020
Pathology (U vs. D) 0.139 1.929 0.808 4.605 Pathology (U vs. D) 0.401 1.509 0.578 3.941
T stage (T3-4 vs. T1-2) 0.144 1.686 0.837 3.395 T stage (T3-4 vs. T1-2) 0.370 1.408 0.667 2.974
N stage (N2-3 vs. N0-1) 0.011 2.389 1.221 4.671 N stage (N2-3 vs. N0-1) 0.008 3.054 1.341 6.955
Clinical stage (III~IVb vs. I~II) 0.045 5.545 1.041 29.541 Clinical stage (III~IVb vs. I~II) 0.069 2.569 0.928 7.111
Fli-1 (positive vs. negative) 0.031 2.076 1.068 4.037 Fli-1 (positive vs. negative) 0.042 2.445 1.032 5.793
AER (N49% vs.≤49%) 0.082 2.175 0.906 5.220 AER (N49% vs.≤49%) 0.233 1.745 0.698 4.362
Chemotherapy (yes vs. no) 0.907 0.941 0.339 2.609 Chemotherapy (yes vs. no) 0.186 2.261 0.675 7.580
II OS II DMFS
Age (years) (N50 vs. ≤50) 0.377 1.432 0.646 3.173 Age (years) (N50 vs. ≤50) 0.823 1.108 0.452 2.713
Gender (female vs. male) 0.414 0.707 0.308 1.624 Gender (female vs. male) 0.048 0.290 0.085 0.991
Pathology (U vs. D) 0.166 1.825 0.780 4.272 Pathology (U vs. D) 0.420 1.463 0.580 3.691
Clinical stage (III~IVb vs. I~II) 0.014 5.074 1.386 18.572 Clinical stage (III~IVb vs. I~II) 0.035 2.820 1.074 7.401
Fli-1 (positive vs. negative) 0.039 2.017 1.037 3.922 Fli-1 (positive vs. negative) 0.045 2.337 1.020 5.355
AER (N49% vs.≤49%) 0.072 2.155 0.933 4.976 AER (N49% vs.≤49%) 0.233 1.696 0.712 4.039
Chemotherapy (yes vs. no) 0.990 0.994 0.370 2.668 Chemotherapy (yes vs. no) 0.188 2.236 0.675 7.410
Abbreviations: OS, overall survival; DMFS, distant metastasis-free survival; HR, hazard ratio; CI, confidence interval; U, undifferentiated non-keratinized carcinoma; D, differentiated non-keratinized
carcinoma; vs., versus. AER denotes serologic antienzyme rate of Epstein-Barr virus DNase-specific neutralizing antibody.
Figure 3. Survival curves of nasopharyngeal carcinoma patients in the training set stratified by clinical stage. All survival rates were well
separated by clinical stage. (A) Overall survival curves of patients with I~II stage and III~IVb stage; (B) Distant metastasis-free survival
curves of patients with I~II stage and III~IVb stage; (C) Progression-free survival curves of patients with I~II stage and III~IVb stage;
(D) Locoregional failure-free survival curves of patients with I~II stage and III~IVb stage.
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Figure 4. Survival curves of nasopharyngeal carcinoma patients in the training set stratified by supplementing FLI-1 with clinical stage.
Theprognosesof patients in the training setwereclearly discriminatedbyFLI-1 expression and clinical stage. (A)Overall survival curves for the
L, IL, IH andH subgroups; (B) Distantmetastasis-free survival curves for the L, IL, IH andH subgroups; (C) Progression-free survival curves for
the L, IL, IH and H subgroups; (D) Locoregional failure-free survival curves for the L, IL, IH and H subgroups. Abbreviation: L, low risk; IL,
intermediate-low risk; IH, intermediate-high risk; H, high risk.
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FLI-1 expression group and the negative FLI-1 expression group were
52% and 78% (P=0.010), respectively. The 6-year PFS rates for the
positive FLI-1 expression group and the negative FLI-1 expression group
were 54% and 77% (P=0.031), respectively. However, no significant
differences in the 6-year LRFS rates were indicated, with 72% and 88%
(P=0.076) for the positive and negative FLI-1expression groups,
respectively. The survival curves were shown in Figure 2A-D.Univariate and Multivariate Analysis with the COX
Proportional Hazards Model
Univariate analyses was performed by the COX proportional hazards
model to test if gender, age, pathological type, T stage, N stage, clinical
stage, AER, chemotherapy or FLI-1 expression was associated with OS,
DMFS, PFS or LRFS in the training set. The results showed that N
stage, clinical stage and FLI-1 expression were prognostic factors for OS,
DMFS and PFS. Gender was a prognostic factor for both DMFS and
PFS. T stage, which had a borderline significance in LRFS, was
significantly associated with PFS. Advanced clinical stage was also
associated with poor LRFS (Table 2).In the training set, multivariate analyses was performed by the COX
proportional hazards model to determine the independent prognostic
factors of NPC, including all the factors analyzed in the univariate
analysis. The results indicated that N stage, clinical stage and FLI-1
expression were independently significant for OS. N stage and FLI-1
expression were independent predictors for DMFS. Further COX
proportional hazards model analysis was required because of the
interactive effects between clinical stage and T/N stage, which included
clinical stage and the rest clinical characteristics except T stage and N
stage. The results showed that both clinical stage and FLI-1 expression
were independent predictors for both OS and DMFS (Table 3).FLI-1 Expression Discriminates the Prognoses of a Subgroup
with Similar Clinical Stage
Patients were divided into two groups according to clinical stage
(I~II versus III~IVb). Survival analysis was performed to the training
set, with the result indicating that clinical stage distinguished all
survival curves well (Figure 3A-D). Patients in the training set were
further stratified based on FLI-1 expression. Survival analysis with
Kaplan-Meier method and log-rank test showed that the prognoses of
Figure 5. Survival curves of nasopharyngeal carcinoma patients in the testing set stratified by supplementing FLI-1 with clinical stage. The
prognoses of the patients in the testing set were separated by FLI-1 expression and clinical stage. (A) Overall survival curves for the L, IL,
IH and H subgroups; (B) Distant metastasis-free survival curves for the L, IL, IH and H subgroups; (C) Progression-free survival curves for
the L, IL, IH and H subgroups; (D) Locoregional failure-free survival curves for the L, IL, IH and H subgroups. Abbreviation: L, low risk; IL,
intermediate-low risk; IH, intermediate-high risk; H, high risk.
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There were four subgroups: low risk (L), with I~II stage and negative
FLI-1 expression; intermediate-low risk (IL), with I~II stage and
positive FLI-1 expression; intermediate-high risk (IH), with III~IVb
stage and negative FLI-1 expression; high risk (H), with III~IVb stage
and positive FLI-1 expression. Similar results were obtained both in
the testing set (Figure 5A-D) and in the whole patients (Figure 6A-D).
These results conformed that supplementing FLI-1 with clinical stage
led to more accurate prognostication of NPC.
Discussion
In this study, we observed that cytoplasmic positive expression of FLI-
1 correlated significantly with advanced N classification and survival
of NPC patients. In addition, OS and DMFS of NPC patients with
positive FLI-1 expression were significantly poorer than those with
negative FLI-1 expression in the multivariate analysis. Incorporating
the clinical stage and FLI-1 expression, by which NPC patients were
classified into four risk subgroups, was more effective and accurate in
predicting prognosis for NPC than clinical stage alone, especially for
patients with III~IVb stage diseases. Thus, FLI-1 has potential as a
biomarker to facilitate individualized treatment of NPC. To ourknowledge, we were the first to evaluate FLI-1 expression in NPC
tissue and analyze the associations between FLI-1 expression and
clinicopathological characteristics and prognosis.
Various benign and malignant neoplasms, especially Ewing’sarcoma/
primitive neuroectodermal tumor (EWS/PNET) [11], positively
expressed FLI-1, a proto-oncogene, which was negatively expressed in
most normal tissues except lymph node, spleen and blood vessel
endothelium. FLI-1 is still considered as a sensitive and specific
biomarker for diagnosing EWS/PNET currently. This study indicated
that FLI-1 protein was localized in the cytoplasm of NPC cells,
consistent with the study by Shintani et al [12], who observed
cytoplasmic FLI-1 expression in the oral squamous cell cancer
(OSCC). In our study, the incidence of positive FLI-1 expression was
33.3% (66/198), higher than previously reported 5.3% (27/508) in
the total squamous cell carcinoma [11], but lower than 53.8% (14/26)
in OSCC [12]. NPC is a kind of malignant tumor originating from
nasopharyngeal mucosa stratified squamous epithelium. All patients in
this study were diagnosed as undifferentiated non-keratinized carcino-
ma (189/198) or differentiated non-keratinized carcinoma (9/198), but
in NPC tissue specimens, small portion of adenoid-like differentiated
tumor was occasionally observed (5/198). In addition, all the adenoid-
Figure 6. Survival curves of all nasopharyngeal carcinoma patients stratified by supplementing FLI-1 with clinical stage. The prognoses of
the 198 patients were clearly discriminated by FLI-1 expression and clinical stage. (A) Overall survival curves for the L, IL, IH and H
subgroups; (B) Distant metastasis-free survival curves for the L, IL, IH and H subgroups; (C) Progression-free survival curves for the L, IL,
IH and H subgroups; (D) Locoregional failure-free survival curves for the L, IL, IH and H subgroups. Abbreviation: L, low risk; IL,
intermediate-low risk; IH, intermediate-high risk; H, high risk.
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negative expression in the peripheral carcinoma nests, which was similar
to the previous result that adenocarcinoma strongly expressed FLI-1
[11]. These findings suggested that FLI-1 might play an important but
unclear role in the development and progression of NPC. FLI-1
expression correlated with advanced N classification and metastasis.
Patients with FLI-1 positive expression tended to have lower or bilateral
neck lymph node metastasis or large lymph nodes, and were likely to be
afflicted by distant metastasis after definitive radiotherapy. These results
suggested that cancer cells might have acquired the capacity of
proliferating faster and higher malignancy degree when FLI-1 was
positively expressed. Our findings were previously confirmed in
melanoma and a NPCmetastatic cell line, respectively. Torlakovic et
al found that FLI-1 expression was detected in all melanoma cell lines
and higher in metastatic tumors than in the primary ones. FLI-1
expression also positively correlated with Ki-67 expression and the
presence of an ulcer in the primary tumor, which were both the
independent adverse prognostic factors for melanoma [8]. Yang et al
discovered that FLI-1 were differentially expressed in the metastatic
5-8F and non-metastatic 6-10B NPC cell lines, and confirmed
positive expression of FLI-1 in 5-8F cells through subtractive suppressionhybridization, reverse Northern blotting and cDNA fragments analysis
[14]. These up-mentioned studies hinted FLI-1 might be involved in the
tumor progression and metastasis.
One of the leading causes of tumor-related death is distant metastasis,
which is closely associated with abnormal angiogenesis, hypoxia and
radioresistance [15]. ETS family plays a key role in the endothelial-specific
gene expression regulation, as its family members have binding sites in
many known endothelial-specific enhancers, including the endothelial
enhancers in the human genome [16]. The expression of FLI-1 has been
detected in the hematopoietic cells and endothelial cells at the very early
development stage. FLI-1 binds to specific enhancers, activates
endothelium-related gene expression and induces embryonic stem cells
differentiate towards endothelial progenitor cells [17]. In our study,
typical tumor angiogenesis and FLI-1 expression in the vascular
endothelium were difficult to evaluate because of the insufficiency of
biopsy NPC specimen onmost tissue sections. However, the finding that
FLI-1 was highly expressed in the adenoid-like differentiated NPC
suggested that NPC cancer cell might had developed like adenoid-like
endothelium through FLI-1 related gene expression. EWS/FLI-1 fusion
gene promotes tumor angiogenesis through upregulating VEGF-A
expression [13]. Disorganized angiogenesis exacerbates tumor hypoxia,
502 Prognostic Significance of FLI-1 Liang et al. Translational Oncology Vol. 7, No. 4, 2014which mediates cancer cells invasion, metastasis [18] and resistance to
radiotherapy and cytotoxic drugs [19]. In our study, FLI-1 expression was
associated with poorer OS, DMFS and PFS; multivariate analysis further
confirmed the independent prognostic value of FLI-1 in NPC in the
training set.
Accurate prognostication is urgently needed for individualized
treatment. The TNM staging system is the mainstay for survival
prediction, although it can not always meticulously distinguish the risk.
Several biomarkers have been recognized as valuable prognostic factors of
NPC patients. For example, Zhou et al identified that baseline serum
lactate dehydrogenase level was a reliable predictor of inferior survival and
subsequent liver metastasis for locally advancedNPC patients [20]. In the
study by Xu et al, supplementing pretreatment serologic antienzyme rate
of Epstein-Barr virus DNase-specific neutralizing antibody with TNM
staging system further accurately defined the risk of metastasis, local
failure, progression and death in NPC patient subgroups [21]. Herein,
FLI-1 expression segregated two distinguished subgroups within similar
clinical stages in the training set, comparing the OS, DMFS, PFS and
LRFS. The testing set was used to verify the accuracy of FLI-1 in risk
grouping for OS, DMFS, PFS and LRFS. The disease progression and
survival ofNPCpatientswere also better predictedwith FLI-1 and clinical
classification in the testing set. The results were further validated in a set
containing all the NPC patients. The findings suggested that FLI-1
expression, complementing clinical classification, had potential as a novel
biomarker in prognostication of NPC.
Conclusions
In summary, our study revealed the expression of FLI-1 in NPC, and
found that FLI-1 expression significantly correlated with advanced N
classification, distant metastasis and death. Multivariate analysis showed
that FLI-1 was also an independent prognosticator for poor OS and
DMFS. Incorporation FLI-1 with clinical stage enabled accurate
stratification of NPC patients into four subgroups with different risk
levels of death, distant metastasis and progression in the training, testing
and whole set. Before FLI-1 is eventually applied in clinical practice, the
mechanism by which FLI-1 is involved in the carcinogenesis and
progression ofNPC should be clarified and all results need to be replicated
in a different NPC population.
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